Pharma Blog Watch
Post
market Quarterbacking: The Lazy Person's Science (DrugWonks.com)
Most adverse
events are the result of dumb prescribing, dumb patients or both. At least that's
what blogger Robert Goldberg writes in his short, but pointed, assessment of postmarket
surveillance. Co-blogger Peter Pitts offers up an excerpt from the Wall Street
Journal on the same topic.
Good
Time to Move on Plan B (EyeOnFDA.com)
If Lester Crawford was the obstacle
to approving Barr Pharmaceutical's controversial Plan B oral contraceptive for
OTC status, why hasn't anyone else at the agency picked up the ball? Blogger Mark
Senak raises that question and others about Plan B in his May 30 posting.
Grading the
FDA (Pharma Marketing Blog)
In the wake of a recent survey revealing that
the public gives the FDA a "C," the pharmaceutical industry needs to
do a better job communicating risk information in DTC advertising, according to
blogger John Mack. The industry also needs to help the FDA frame guidelines and
regulations for doing this.